Brown Brothers Harriman & Co. Sells 90,292 Shares of Kenvue Inc. (NYSE:KVUE)

Brown Brothers Harriman & Co. lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 18.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 397,589 shares of the company’s stock after selling 90,292 shares during the period. Brown Brothers Harriman & Co.’s holdings in Kenvue were worth $9,196,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Leo Wealth LLC increased its holdings in shares of Kenvue by 0.3% in the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after acquiring an additional 481 shares during the period. Massmutual Trust Co. FSB ADV boosted its position in Kenvue by 6.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after purchasing an additional 492 shares in the last quarter. Wolff Wiese Magana LLC grew its stake in Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after purchasing an additional 501 shares during the last quarter. Marathon Capital Management raised its holdings in Kenvue by 0.3% in the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after purchasing an additional 514 shares in the last quarter. Finally, Poehling Capital Management INC. raised its holdings in Kenvue by 0.5% in the second quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock worth $1,908,000 after purchasing an additional 547 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Up 0.1 %

Kenvue stock opened at $24.11 on Monday. The business’s 50-day simple moving average is $22.84 and its two-hundred day simple moving average is $20.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market cap of $46.23 billion, a PE ratio of 43.78, a PEG ratio of 2.19 and a beta of 1.36. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.31.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the prior year, the firm earned $0.31 earnings per share. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. Equities analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KVUE. UBS Group raised their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Bank of America raised their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft upped their price target on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Piper Sandler raised their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. Finally, Jefferies Financial Group started coverage on Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.